Melanocyte-directed enzyme prodrug therapy (MDEPT): development of a targeted treatment for malignant melanoma

Bioorg Med Chem. 1999 Sep;7(9):1775-80. doi: 10.1016/s0968-0896(99)00126-1.


A novel prodrug rationally designed to function as a tyrosinase substrate has been synthesised to allow targeted treatment of malignant melanoma. This agent has been evaluated for tyrosinase-mediated drug release, and has been shown to act in the desired manner. Furthermore, differential cytotoxicity has been demonstrated in cell lines which express tyrosinase and those which do not.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • CHO Cells
  • Cricetinae
  • Magnetic Resonance Spectroscopy
  • Melanocytes / drug effects*
  • Melanoma / drug therapy*
  • Melanoma / enzymology
  • Monophenol Monooxygenase / metabolism
  • Prodrugs / pharmacology
  • Prodrugs / therapeutic use*
  • Tumor Cells, Cultured


  • Prodrugs
  • Monophenol Monooxygenase